Tesamorelin 15mg — Vial Spec, Reconstitution Math & COA

Tesamorelin 15mg Specifications and Availability Overview

A 15mg vial of Tesamorelin contains 15 milligrams of highly purified, lyophilized trans-3-hexenoic acid-substituted growth hormone-releasing hormone (GHRH) analog. Designed specifically for long-term or high-throughput laboratory research, this vial configuration allows research facilities to perform multi-subject rodent assays or extended in vitro incubations without requiring frequent vial changes. The 15mg mass load minimizes container-closure variability across extensive trial blocks, ensuring consistent compound availability across identical experimental conditions.

While PX1 Research maintains a core inventory featuring the standardized Tesamorelin 10mg format, understanding the volumetric math and handling requirements of a 15mg specification remains critical for bench scientists scaling up their protocols. Laboratories seeking specific batch sizes, custom fills, or alternate mass configurations can browse our full catalog of all peptides or request tailored production runs. Every compound supplied by PX1 Research is strictly designated for laboratory research use only and is not intended for human or veterinary applications.

When handling 15mg peptide vials, maintaining structural integrity during reconstitution and storage is paramount. The hexenoyl moiety attached to the N-terminus of the 44-amino acid peptide chain increases enzymatic stability compared to native GHRH, but improper dilution or thermal exposure can still lead to aggregation or peptide degradation. Institutional researchers rely on exact mass-to-volume calculations to ensure precision across every micro-aliquot.

Biochemical Structure and Mechanism of Action

Tesamorelin is a synthetic analog of human growth hormone-releasing factor (GRF) composed of 44 amino acids with an added trans-3-hexenoic acid group at the N-terminal tyrosine residue. This lipophilic modification protects the peptide against rapid cleavage by dipeptidyl peptidase-IV (DPP-IV), substantially extending its biological half-life in preclinical test systems compared to endogenous GHRH (1-44). In vitro binding assays demonstrate that Tesamorelin retains full agonist activity at the GHRH receptor (GHRHR) located on anterior pituitary somatotrophs.

Preclinical studies suggest that activation of the GHRH receptor by Tesamorelin triggers the G-protein-coupled adenylyl cyclase/cAMP/protein kinase A signaling pathway. This cascade induces the transcription and pulsatile release of endogenous growth hormone (GH), which subsequently stimulates hepatic synthesis of insulin-like growth factor 1 (IGF-1). Animal models evaluating metabolic regulation indicate that this axis activation plays a significant role in lipolysis, nitrogen retention, and cellular repair processes.

Because Tesamorelin acts upstream at the pituitary level rather than directly activating peripheral GH receptors, it preserves natural negative feedback loops mediated by somatostatin and IGF-1. In vitro data indicate that this receptor-mediated feedback prevents continuous, non-pulsatile GH spikes, making the compound a valuable model for investigating physiological growth hormone regulation, lipid substrate oxidation, and tissue-repair mechanics without inducing total feedback axis suppression.

Reconstitution Mathematics for 15mg Mass Loads

Accurate reconstitution of a 15mg lyophilized cake requires precise volumetric measurement using sterile diluents such as Bacteriostatic Water (0.9% benzyl alcohol) or Sterile 0.9% Sodium Chloride. The target concentration determines the volumetric withdrawal required for specific assay working loads. Scientists can utilize the PX1 reconstitution calculator to quickly model custom volumetric ratios and microgram-per-microliter metrics.

To establish a standard 15mg dilution workflow, consider the following common diluent volumes added to a 15mg vial of lyophilized compound:

• 1.0 mL Diluent Volume: Reconstitution with 1.0 mL yields a final peptide concentration of 15.0 mg/mL (15,000 µg/mL). In this high-density matrix, a 10 µL volume delivers exactly 150 µg of compound. This concentration is frequently selected for automated micro-dispensing setups or low-volume micro-injection models in preclinical rodents.

• 2.0 mL Diluent Volume: Adding 2.0 mL of solvent results in a concentration of 7.5 mg/mL (7,500 µg/mL). At this concentration, a 20 µL working volume yields 150 µg of active peptide, balancing ease of volumetric pipetting with minimal liquid volume displacement.

• 3.0 mL Diluent Volume: Reconstituting with 3.0 mL produces a concentration of 5.0 mg/mL (5,000 µg/mL). A 100 µL volume provides exactly 500 µg (0.5 mg) of Tesamorelin. This lower viscosity configuration is ideal for manual multi-channel pipetting across standard 96-well cell culture plates.

Aliquot Planning and Laboratory Handling Protocols

Given the large 15mg payload, reconstituting the entire vial into a single working vessel requires a clear aliquot strategy to prevent repeated freeze-thaw cycles. Subjecting reconstituted GHRH analogs to multiple thermal shifts induces physical stress that promotes peptide aggregation, deamidation, and loss of receptor-binding potency. Research teams should plan single-use or weekly sub-aliquots immediately following initial reconstitution.

When transferring reconstituted solutions, researchers should utilize low-binding polypropylene microcentrifuge tubes to prevent peptide adsorption onto tube walls. Diluent should be directed down the glass wall of the original vial rather than sprayed directly onto the lyophilized cake. Gentle swirly rotation is recommended to achieve complete dissolution; mechanical vortexing must be strictly avoided as shear forces can disrupt the tertiary structure of the 44-amino-acid peptide chain.

If an assay schedule spans several weeks, reconstituted aliquots not intended for immediate use within 48 to 72 hours should be flash-frozen using liquid nitrogen or a dry ice/ethanol bath and stored at -20°C to -80°C. Aliquots designated for immediate daily bench use should be maintained at 2°C to 8°C under light-protected conditions.

Quality Assurance, COA Verification, and Testing Standards

Every batch of research peptides distributed by PX1 Research undergoes comprehensive analytical testing to verify identity, purity, and safety profile. Chemical integrity is confirmed using High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS). To review batch-specific analytical documentation, researchers can access our dedicated COA verification page to inspect lot-matched chromatograms and mass spectra.

Our analytical verification protocols mandate a minimum purity threshold of ≥98.0% by HPLC area normalization. Mass spectrometry analysis verifies that the observed molecular weight matches the theoretical target of approximately 5135.9 Da (free base equivalent), confirming correct amino acid sequencing and successful hexenoyl conjugation without truncated sequences or incomplete synthesis byproducts.

In addition to purity and identity testing, PX1 Research subjects all peptide lots to chromogenic Limulus Amebocyte Lysate (LAL) assays for bacterial endotoxin quantification. Products manufactured in our ISO 17025 accredited and GMP-compliant facilities maintain endotoxin levels well below established research thresholds (<0.05 EU/mg), ensuring that cellular assays and animal models remain free from confounding inflammatory artifacts.

Storage Protocols and Thermal Stability Matrix

Lyophilized Tesamorelin displays robust stability when stored under appropriate thermal conditions. Upon receipt at the laboratory facility, unopened lyophilized vials should be placed in sub-zero storage at -20°C for short-to-medium term storage (up to 12 months) or -80°C for long-term archiving. Vials must be kept away from intense ambient light, moisture, and fluctuating temperatures within frost-free freezer cycles.

The following matrix outlines the recommended storage parameters for Tesamorelin 15mg across different physical states:

• Lyophilized Powder (-20°C to -80°C): Stable for up to 24 months. Protect from desiccating environments and ambient light exposure.

• Lyophilized Powder (2°C to 8°C Refrigerated): Stable for up to 90 days. Recommended only for vials scheduled for reconstitution within a short operational window.

• Reconstituted Solution in Bacteriostatic Water (2°C to 8°C): Stable for up to 28 days when preserved with benzyl alcohol. Maintain strict aseptic conditions.

• Reconstituted Solution in Sterile Normal Saline (2°C to 8°C): Stable for up to 24 to 48 hours; unpreserved solutions must be utilized promptly to avoid microbial growth or peptide degradation.

• Frozen Reconstituted Aliquots (-20°C to -80°C): Stable for up to 3 to 6 months. Avoid repeated freeze-thaw steps.

Comparative Class Analysis: GHRH Analogs and Growth Hormone Secretagogues

When designing preclinical protocols investigating the somatotropic axis, researchers frequently evaluate multiple secretagogues to compare receptor kinetics, half-life parameters, and downstream physiological signaling. Tesamorelin belongs to the GHRH class, but its structural modification yields distinct performance characteristics compared to other peptides in the growth hormone secretagogue category.

A comparison of related research compounds includes:

• Tesamorelin: A hexenoyl-modified GHRH (1-44) analog engineered for extended enzymatic stability. Demonstrates high specificity for pituitary GHRH receptors, stimulating pulsatile GH release with marked preclinical effects on visceral adiposity and tissue-repair biomarkers.

• CJC-1295 No DAC: A modified 29-amino-acid GHRH analog (Tetrasubstituted GRF 1-29). Provides a shorter plasma half-life than DAC-bound variants, making it suitable for mimicking natural, transient physiological GH spikes when co-administered with ghrelin mimetics.

• Sermorelin: The truncated 29-amino-acid sequence (GHRH 1-29) representing the naturally occurring catalytic domain of endogenous GHRH. Exhibits a rapid clearance rate in preclinical models, ideal for short-duration acute signaling studies.

• Ipamorelin: A selective pentapeptide Ghrelin/Growth Hormone Secretagogue Receptor (GHS-R) agonist. Acts via a complementary pathway distinct from GHRH analogs, often evaluated alongside GHRH peptides in synergistic dual-pathway secretagogue assays.

In preclinical trials comparing these agents, Tesamorelin consistently demonstrates superior resistance to DPP-IV degradation relative to Sermorelin, while maintaining a more physiological pulsatile GH release profile than long-acting Drug Affinity Complex (DAC) formulations.

Preclinical Research Contexts and Scientific Literature

In scientific literature, Tesamorelin is extensively studied across several distinct domains of metabolic and regenerative biology. Primary research focus areas include its capacity to alter body composition markers in rodent models, specifically through the reduction of visceral adipose tissue (VAT) without disrupting overall glucose homeostasis.

In vitro data indicate that elevated GH secretion downstream of Tesamorelin binding accelerates lipolysis in adipocytes by upregulating hormone-sensitive lipase (HSL) and downregulating lipoprotein lipase (LPL). Furthermore, rodent studies investigating tissue repair reveal that increased circulating IGF-1 levels correlate with enhanced satellite cell proliferation in skeletal muscle tissue and accelerated collagen synthesis in damaged connective matrix assays.

Researchers exploring the growth hormone axis can examine additional technical references and study summaries in the PX1 research library. These compiled data sets offer benchmark values for receptor binding affinities, downstream target gene expression profiles, and analytical methodology guidelines across modern peptide biochemistry.

Institutional Supply, Custom Fills, and Procurement Standards

PX1 Research serves academic institutions, contract research organizations (CROs), and private biotechnology laboratories across the United States. All products are manufactured in USA-based, GMP-compliant facilities utilizing state-of-the-art solid-phase peptide synthesis (SPPS) technology. Orders processed Monday through Friday before cut-off times qualify for same-day dispatch from our centralized logistics facilities in California and Arizona.

For institutions requiring high-volume supplies, specific vial fill capacities (such as 15mg bulk configurations), or custom synthesis services, our team provides dedicated support through our wholesale portal. Custom packaging, specialized lyophilization parameters, and full lot traceability ensure that large-scale research projects maintain seamless continuity and regulatory compliance throughout their operational lifecycle.